Circulating tumor DNA (ctDNA) has become a valuable biomarker across various cancer types, including B cell lymphomas. Liquid biopsy applications encompass early detection, noninvasive genotyping, classification of tissue and cell of origin, quantification of pretreatment ctDNA levels to assess tumor burden, as well as identification of minimal residual disease (MRD) and relapse. In this presentation, data supporting the clinical utility of ctDNA profiling in large B-cell lymphomas and classic Hodgkin lymphoma will be reviewed.
